Fatty Liver Treatment Market Research Report: Market size, Industry outlook, Market Forecast, Demand Analysis,Market Share, Market Report 2018-2023
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Fatty Liver Treatment Market
Fatty Liver Treatment Market: By Drug (Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated fatty acids, Angiotensin receptor blockers and Pentoxifylline); By End-User (Hospitals and Clinics) & By Region (Europe, Others) - Forecast(2018 - 2023)
Report Code : HCR 0211
Updated Date: 16 May, 2018  

1. Fatty Liver Treatment Market –Overview
2. Executive Summary 
3. Fatty Liver Treatment Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Fatty Liver Treatment Market–Forces
   4.1. Drivers
      4.1.1. Cost Effective Treatment Procedures
      4.1.2. Advancement in Technology
   4.2. Restraints
      4.2.1. Side-Effects
   4.3. Opportunities
      4.3.1. Increasing Incidence of Alcohol Related Diseases
   4.4.  Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Fatty Liver Treatment Market, By Drug 
   5.1. Thiazolidinedione
   5.2. Vitamin E
   5.3. Metformin
   5.4. Statins
   5.5. Polyunsaturated fatty acids
   5.6. Angiotensin receptor blockers
   5.7. Pentoxifylline
6. Fatty Liver Treatment Market, By End-Use 
   6.1. Hospitals
   6.2. Clinics
7. Fatty Liver Treatment Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America 
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Fatty Liver Treatment – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles
   9.1. Cardax, Inc.
      9.1.1. Introduction
      9.1.2. Financials
      9.1.3. Key Insights
      9.1.4. Key Strategy
      9.1.5. Product Portfolio
      9.1.6. SWOT Analysis
   9.2. Daewoong Co., Ltd.
      9.2.1. Introduction
      9.2.2. Financials
      9.2.3. Key Insights
      9.2.4. Key Strategy
      9.2.5. Product Portfolio
      9.2.6. SWOT Analysis
   9.3. Hoffmann-La Roche Ltd.
      9.3.1. Introduction
      9.3.2. Financials
      9.3.3. Key Insights
      9.3.4. Key Strategy
      9.3.5. Product Portfolio
      9.3.6. SWOT Analysis
   9.4. Glenmark
      9.4.1. Introduction
      9.4.2. Financials
      9.4.3. Key Insights
      9.4.4. Key Strategy
      9.4.5. Product Portfolio
      9.4.6. SWOT Analysis
   9.5. GW Pharmaceuticals
      9.5.1. Introduction
      9.5.2. Financials
      9.5.3. Key Insights
      9.5.4. Key Strategy
      9.5.5. Product Portfolio
      9.5.6. SWOT Analysis
   9.6. Limerick BioPharma, Inc.
      9.6.1. Introduction
      9.6.2. Financials
      9.6.3. Key Insights
      9.6.4. Key Strategy
      9.6.5. Product Portfolio
      9.6.6. SWOT Analysis
   9.7. Merck & Co., Inc.
      9.7.1. Introduction
      9.7.2. Financials
      9.7.3. Key Insights
      9.7.4. Key Strategy 
      9.7.5. Product Portfolio
      9.7.6. SWOT Analysis
   9.8. Novartis AG
      9.8.1. Introduction
      9.8.2. Financials
      9.8.3. Key Insights
      9.8.4. Key Strategy
      9.8.5. Product Portfolio
      9.8.6. SWOT Analysis
   9.9. Orchid Chemicals & Pharmaceuticals Ltd
      9.9.1. Introduction
      9.9.2. Financials
      9.9.3. Key Insights
      9.9.4. Key Strategy
      9.9.5. Product Portfolio
      9.9.6. SWOT Analysis
   9.10. AstraZeneca
      9.10.1. Introduction
      9.10.2. Financials
      9.10.3. Key Insights
      9.10.4. Key Strategy
      9.10.5. Product Portfolio
      9.10.6. SWOT Analysis
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Please select Licence
Single User Licence:
US $5250
Corporate User Licence:
US $7250
Related Reports
0px;">Scroll